Skip to main content
Erschienen in: Wiener klinische Wochenschrift 19-20/2013

01.10.2013 | original article

Human papillomavirus in high-grade cervical lesions: Austrian data of a European multicentre study

verfasst von: Lucia Rössler, Assoc. Prof. Olaf Reich, Assoc. Prof. Reinhard Horvat, Sabrina Collas de Souza, Katsyarina Holl, PhD, Elmar A. Joura, MD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 19-20/2013

Einloggen, um Zugang zu erhalten

Summary

Background

The purpose is to present the Austrian data of an observational, cross-sectional, multicentre study conducted in 13 European countries. This study was undertaken to assess human papillomavirus (HPV) type distribution in high-grade cervical lesions.

Methods

Two hundred and ninety cases of high-grade cervical intraepithelial neoplasia (CIN2, CIN3) or adenocarcinoma in situ of the cervix from 2004 to 2007 were analysed by histopathological review and polymerase chain reaction for HPV.

Results

Two hundred and nine cases were “histologically eligible” and of those 206 were HPV+. Median age was 34 years (19–76 years). CIN3 was the most frequent diagnosis (64.6 %), followed by CIN2/3 (19.4 %) and CIN2 (13.6 %). Adenocarcinoma in situ was only detected together with a squamous lesion in 2.4 % cases. Majority of women (75.2 %) were infected with a single HPV type, 98.1 % of them with high-risk HPV types: HPV 16 (56.1 %), HPV 33 (12.3 %), HPV 31 (11.0 %), HPV 18 (3.9 %), HPV 35 (3.9 %), HPV 51 (3.2 %) and HPV 52 (2.6 %), HPV 58 (1.9 %) and HPV 45 (0.6 %). The low-risk HPV 6 was found in 1.3 % cases. Forty-six lesions (22.3 %) contained multiple infections, 71.1 % of those were HPV 16 or 18 and 91.1 % were HPV 16, 18, 31, 33 or 45 positive.

Conclusions

These Austrian data clearly demonstrate that HPV 16 is the predominant type in high-grade CIN, the immediate precursor lesions of cervical cancer. More than 60 % of the lesions were associated with HPV 16 and 18 and more than 85 % with HPV 16, 18, 31, 33 or 45. The prevalence of adenocarcinoma in situ is underestimated, since its detection is difficult with the current cytology screening.
Literatur
1.
Zurück zum Zitat Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907.PubMedCrossRef Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907.PubMedCrossRef
2.
Zurück zum Zitat Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005;32(Suppl 1):S16–24.PubMedCrossRef Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005;32(Suppl 1):S16–24.PubMedCrossRef
3.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55:74–108.PubMedCrossRef Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55:74–108.PubMedCrossRef
4.
Zurück zum Zitat Regauer S, Reich O. CK17 and p16 expression patterns distinguish (atypical) immature squamous metaplasia from high-grade cervical intraepithelial neoplasia (CIN III). Histopathology. 2007;50(5):629–35.PubMedCrossRef Regauer S, Reich O. CK17 and p16 expression patterns distinguish (atypical) immature squamous metaplasia from high-grade cervical intraepithelial neoplasia (CIN III). Histopathology. 2007;50(5):629–35.PubMedCrossRef
5.
Zurück zum Zitat Reich O, Pickel H, Regauer S. Why does HPV infection induce sharply demarcated lesions of the cervix? J Low Genit Tract Dis. 2008;12:8–10.PubMedCrossRef Reich O, Pickel H, Regauer S. Why does HPV infection induce sharply demarcated lesions of the cervix? J Low Genit Tract Dis. 2008;12:8–10.PubMedCrossRef
6.
Zurück zum Zitat Reich O, Pickel H. Multifocal stromal invasion in microinvasive squamous cell carcinoma of the cervix: how to measure and stage these lesions. Int J Gynecol Pathol. 2002;21:416–7.PubMedCrossRef Reich O, Pickel H. Multifocal stromal invasion in microinvasive squamous cell carcinoma of the cervix: how to measure and stage these lesions. Int J Gynecol Pathol. 2002;21:416–7.PubMedCrossRef
7.
Zurück zum Zitat Reich O, Pickel H, Tamussino K, Winter R. Microcarcinoma of the cervix: first focus of invasion. Obstet Gynecol. 2001;97:890–2.PubMedCrossRef Reich O, Pickel H, Tamussino K, Winter R. Microcarcinoma of the cervix: first focus of invasion. Obstet Gynecol. 2001;97:890–2.PubMedCrossRef
8.
Zurück zum Zitat McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9(5):425–34.PubMedCrossRef McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9(5):425–34.PubMedCrossRef
9.
Zurück zum Zitat Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621–32.PubMedCrossRef Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621–32.PubMedCrossRef
10.
Zurück zum Zitat Tjalma WA, Fiander A, Reich O, et al.; HERACLES/SCALE Study Group. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer. 2013;132(4):854–67. Tjalma WA, Fiander A, Reich O, et al.; HERACLES/SCALE Study Group. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer. 2013;132(4):854–67.
11.
Zurück zum Zitat Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17(8):857–72.PubMedCrossRef Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17(8):857–72.PubMedCrossRef
12.
Zurück zum Zitat Zechmeister I. Ökonomische Evaluation der Impfung gegen humane Papillomaviren (HPV- Impfung) in Österreich. Endbericht des Ludwig Boltzmann Instituts für Health Technology Assessment (LBI-HTA) 2007;26. Zechmeister I. Ökonomische Evaluation der Impfung gegen humane Papillomaviren (HPV- Impfung) in Österreich. Endbericht des Ludwig Boltzmann Instituts für Health Technology Assessment (LBI-HTA) 2007;26.
13.
Zurück zum Zitat Leitner B. Statistik Austria, Jahrbuch der Gesundheitsstatistik 2010. Vienna: Statistik Austria; 2011. Leitner B. Statistik Austria, Jahrbuch der Gesundheitsstatistik 2010. Vienna: Statistik Austria; 2011.
14.
Zurück zum Zitat Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006;367(9509):489–98.PubMedCrossRef Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006;367(9509):489–98.PubMedCrossRef
15.
Zurück zum Zitat Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ. 2008;337:a1284.PubMedCrossRef Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ. 2008;337:a1284.PubMedCrossRef
16.
Zurück zum Zitat Van Hentenryck M, Noel JC, Simon P. Obstetric and neonatal outcome after surgical treatment of cervical dysplasia. Eur J Obstet Gynecol Reprod Biol. 2012;162(1):16–20.PubMedCrossRef Van Hentenryck M, Noel JC, Simon P. Obstetric and neonatal outcome after surgical treatment of cervical dysplasia. Eur J Obstet Gynecol Reprod Biol. 2012;162(1):16–20.PubMedCrossRef
17.
Zurück zum Zitat Ortoft G, Henriksen T, Hansen E, Petersen L. After conisation of the cervix, the perinatal mortality as a result of preterm delivery increases in subsequent pregnancy. BJOG. 2010;117(3):258–67.PubMedCrossRef Ortoft G, Henriksen T, Hansen E, Petersen L. After conisation of the cervix, the perinatal mortality as a result of preterm delivery increases in subsequent pregnancy. BJOG. 2010;117(3):258–67.PubMedCrossRef
18.
Zurück zum Zitat Six L, Leodolter S, Sings HL, Barr E, Haupt R, Joura EA. Prevalence of Human Papillomavirus Types 6, 11, 16, and 18 in young Austrian Women- the baseline data of a Phase III Vaccine Trial. Wien Klin Wochenschr. 2008;120(21–22):666–71.PubMedCrossRef Six L, Leodolter S, Sings HL, Barr E, Haupt R, Joura EA. Prevalence of Human Papillomavirus Types 6, 11, 16, and 18 in young Austrian Women- the baseline data of a Phase III Vaccine Trial. Wien Klin Wochenschr. 2008;120(21–22):666–71.PubMedCrossRef
19.
Zurück zum Zitat Herzog TJ, Monk BJ. Reducing the burden of glandular carcinomas of the uterine cervix. Am J Obstet Gynecol. 2007;197(6):566–71.PubMedCrossRef Herzog TJ, Monk BJ. Reducing the burden of glandular carcinomas of the uterine cervix. Am J Obstet Gynecol. 2007;197(6):566–71.PubMedCrossRef
20.
Zurück zum Zitat Bray F, Carstensen B, Møller H, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2191–9.PubMedCrossRef Bray F, Carstensen B, Møller H, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2191–9.PubMedCrossRef
21.
Zurück zum Zitat Zielonke N. Krebsinzidenz und Krebsmortalität in Österreich 2012. Vienna: Statistik Austria; 2012. Zielonke N. Krebsinzidenz und Krebsmortalität in Österreich 2012. Vienna: Statistik Austria; 2012.
22.
Zurück zum Zitat Ault KA, Joura EA, Kjaer SK, et al.; FUTURE I and II Study Group. Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. Int J Cancer. 2011;128(6):1344–53.PubMedCrossRef Ault KA, Joura EA, Kjaer SK, et al.; FUTURE I and II Study Group. Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. Int J Cancer. 2011;128(6):1344–53.PubMedCrossRef
23.
Zurück zum Zitat Stoler MH, Vichnin MD, Ferenczy A, et al.; FUTURE I, II and III Investigators. The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials. Int J Cancer. 2011;128(6):1354–62.PubMedCrossRef Stoler MH, Vichnin MD, Ferenczy A, et al.; FUTURE I, II and III Investigators. The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials. Int J Cancer. 2011;128(6):1354–62.PubMedCrossRef
24.
Zurück zum Zitat van Doorn LJ, Molijn A, Kleter B, Quint W, Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol. 2006;44:3292–8.PubMedCrossRef van Doorn LJ, Molijn A, Kleter B, Quint W, Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol. 2006;44:3292–8.PubMedCrossRef
25.
Zurück zum Zitat van Doorn LJ, Quint W, Kleter B, et al. Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J Clin Microbiol. 2002;40:979–83.PubMedCrossRef van Doorn LJ, Quint W, Kleter B, et al. Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J Clin Microbiol. 2002;40:979–83.PubMedCrossRef
26.
Zurück zum Zitat Paavonen J, Naud P, Salmerón J, et al.; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–14.PubMedCrossRef Paavonen J, Naud P, Salmerón J, et al.; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–14.PubMedCrossRef
27.
Zurück zum Zitat Lehtinen M, Paavonen J, Wheeler CM, et al.; HPV PATRICIA Study Group. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89–99.PubMedCrossRef Lehtinen M, Paavonen J, Wheeler CM, et al.; HPV PATRICIA Study Group. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89–99.PubMedCrossRef
28.
Zurück zum Zitat FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–27.CrossRef FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–27.CrossRef
29.
Zurück zum Zitat Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three clinical trials. Lancet. 2007;369:1693–702.PubMedCrossRef Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three clinical trials. Lancet. 2007;369:1693–702.PubMedCrossRef
30.
Zurück zum Zitat Joura EA, Garland SM, Paavonen J, et al.; FUTURE I and II Study Group. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ. 2012;27(344):e1401. Joura EA, Garland SM, Paavonen J, et al.; FUTURE I and II Study Group. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ. 2012;27(344):e1401.
31.
Zurück zum Zitat Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis. 2009;199(7):926–35.PubMedCrossRef Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis. 2009;199(7):926–35.PubMedCrossRef
32.
Zurück zum Zitat Wheeler CM, Castellsagué X, Garland SM, et al. HPV PATRICIA Study Group. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):100–10.PubMedCrossRef Wheeler CM, Castellsagué X, Garland SM, et al. HPV PATRICIA Study Group. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):100–10.PubMedCrossRef
33.
Zurück zum Zitat Malagón T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(10):781–9.PubMedCrossRef Malagón T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(10):781–9.PubMedCrossRef
34.
Zurück zum Zitat Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine. 2012;30 Suppl 5:F157–67.PubMedCrossRef Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine. 2012;30 Suppl 5:F157–67.PubMedCrossRef
Metadaten
Titel
Human papillomavirus in high-grade cervical lesions: Austrian data of a European multicentre study
verfasst von
Lucia Rössler
Assoc. Prof. Olaf Reich
Assoc. Prof. Reinhard Horvat
Sabrina Collas de Souza
Katsyarina Holl, PhD
Elmar A. Joura, MD
Publikationsdatum
01.10.2013
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 19-20/2013
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-013-0403-6

Weitere Artikel der Ausgabe 19-20/2013

Wiener klinische Wochenschrift 19-20/2013 Zur Ausgabe

MUW researcher of the month

Researcher of the Month Oktober 2013

mitteilungen der gesellschaft der ärzte in wien

Veranstaltungen